PARP1 and osteosarcoma: Increased apoptosis of osteosarcoma cells by co-treatment of olaparib and doxorubicin was associated with increased expression of cleaved PARP1, cleaved caspase 3, and BAX, and decreased expression of BCL2 (Fig. 7b).